Exhibit 10.22


 


Fourth
Amendment to Supply Agreement


 


This Amendment (this
“Amendment”) effective as of March 11, 2011 (the “Amendment Date”) to the Supply
Agreement (the “Agreement”), entered into on December 8,
2005, and previously amended on February 28, 2006, September 5, 2006, and February 26, 2010, between Hemispherx Biopharma, Inc.
(hereinafter “Hemispherx”), and Jubilant HollisterStier LLC (formerly known as Hollister-Stier Laboratories
LLC (hereinafter “Hollister-Stier”). Hemispherx and Hollister-Stier are each a “Party” and
collectively, the “Parties”.


 


Whereas,
the Parties wish to amend the Agreement regarding, among other things, postponement and cancellation of purchase orders; and


 


Whereas,
all terms used, but not defined, herein shall have the respective meanings set forth in the Agreement.


 


Now,
Therefore, in consideration of the premises and of the covenants herein contained, the Parties mutually agree as follows:


 


		1.	Amendments.



 


(a) Section 3.8.2.2 of the Agreement is amended
and restated in its entirety as follows:


 


3.8.2.2 Hemispherx reserves the right
to cancel or postpone any purchase order, provided that all postponements and cancellations are in accordance with each of the
following terms:


 


		3.8.2.2.1	Should Hemispherx cancel or postpone all or part of any purchase order  * or fewer calendar days prior to the
scheduled fill date, Hemispherx shall pay Hollister-Stier a  *  fee equivalent to   *   of
the purchase price for the entire purchase order.



 


		3.8.2.2.2	Should Hemispherx cancel or postpone all or part of any purchase order less than    *  calendar
days, but more than    *  calendar days prior to the scheduled fill date, Hemispherx shall
pay Hollister-Stier  a  *   fee equal to   *   of the purchase
price for the entire purchase order.



 


		3.8.2.2.3	Should Hemispherx cancel or postpone all or part of any purchase order less than    *  calendar
days, but more than    *  calendar days prior to the scheduled fill date, Hemispherx shall pay Hollister-Stier a  *  fee equal to   *   of the purchase price for the entire purchase order.



 


		3.8.2.2.4	Should Hemispherx cancel or postpone a purchase order    *  or more days before the scheduled
fill date, Hollister-Stier will    *    . 



 


* Portions of this exhibit have been omitted
pursuant to a request for confidential treatment and have been filed separately with the Commission.


 Confidential


 



    	1



    	 



    

 


		3.8.2.2.5	The fees imposed under this Section 3.8.2.2 are    *    that will be imposed upon a
rescheduled purchase order.



 


(b) The following is appended to Section 3.8.3.:
“The prices as of March 11, 2011, which are subject to increase on the next anniversary of the Effective Date are set forth
on Exhibit B.”


 


(c) The Exhibit to this Amendment is appended
to the Agreement, as Exhibit B.


 


(d)
Section 8.1 is amended by replacing such Section with: “This Agreement shall remain in full force and effect for   3  years
from the effective date of this Amendment, unless terminated earlier in accordance with the provisions hereof.


 


		2.	Miscellaneous.



 


2.1          Continuing
Effect. This Amendment shall be effective for all purposes as of the Amendment Date. Except as otherwise expressly modified
by this Amendment, the Agreement shall remain in full force and effect in accordance with its terms.


 


2.2          Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.


 


2.3          Governing
Law. This Amendment shall be governed by and construed in accordance with the laws of the State of Washington, irrespective
of any conflicts of law rule which may direct or refer such determination of applicable law to any other state, and if this Amendment
were performed wholly within the State of Washington.


 


* Portions of this exhibit have been omitted pursuant to a request
for confidential treatment and have been filed separately with the Commission.


 Confidential


 



    	2



    	 



    

 


In
Witness Whereof, the Parties have executed this Amendment effective as of the Amendment Date.


 


	Hemispherx Biopharma, Inc.
	 
	By:	/s/ William A. Carter	 
	 	 	 
	Name:	 William A. Carter, M.D.	 
	 	 	 
	Title:	 CEO	 
	 	 	 
	Date:	 9/9/11	 
	 	 	 
	Jubilant HollisterStier LLC
	 	 	 
	By:	/s/ Marcelo Morales	 
	 	 	 
	Name:	 Marcelo Morales	 
	 	 	 
	Title:	 CEO	 
	 	 	 
	Date:	 Sept 2, 2011	 


 


* Portions of this exhibit have been omitted pursuant to a request
for confidential treatment and have been filed separately with the Commission.


Confidential


 



    	3



    	 



    

 


EXHIBIT TO AMENDMENT FORMING EXHIBIT
B TO SUPPLY AGREEMENT


PRICING AS OF MARCH 11, 2011


 





 


 


	December 8, 2010	


 


Mr. Wayne Springate


Hemispherx Biopharma, Inc.


783 Jersey Ave.


New Brunswick, NJ 08901


 


RE: Document 576-2-25-0, 2011 Price Increase - Ampligen


 


Dear Mr. Springate:


 


Per Supply Agreement dated December 8, 2005, Section 3.8.3, Hollister-Stier
is notifying you of a    *   increase in pricing for fill/finish services provided to Hemispherx
Biopharma. Changes in pricing are based upon the annual percentage change in the Producer Price Index Industry:


Pharmaceutical Preparations. Pricing for product lots manufactured
December 8, 2010 through December 7, 2011 will be as follows:


 


	AMPLIGEN
	CURRENT PRICING	 	PROPOSED PRICING
	Media Fill Batch:	$          *	 	Media Fill Batch:	$          *
	Development Batch:	$          *	 	Development Batch:	$          *
	Registration/Commercial Batches:	$          *	 	Registration/Commercial Batches:	$          *


 


As always, we appreciate your business and
remain dedicated to the high standards of quality you

rely upon. If you have any questions, please feel free to contact me directly at 509-482-3541.


 


Best regards,


/s/David M. Flowers


Director, Business Development


 


DMF/lec


 


* Portions of this exhibit have been omitted pursuant to a request
for confidential treatment and have been filed separately with the Commission.


 Confidential


 



    	4